Light Switch Bio

When a drug is active where it isn’t needed, it can harm the patient. Traditionally, this harm is called a “side effect” and accepted as a necessary evil. We believe that tradition should change. We can make medicines more precise by repurposing them into "photoactivated chemotherapies". To prove the value of our service, we are developing a repurposed version of cisplatin for recurrent head and neck cancers in collaboration with Virginia Commonwealth University's Massey Cancer Center, the University of Pennsylvania, and the Center for Advancing Innovation. We are also seeking new partnerships to investigate other indications or repurposed drugs. Our team is experienced in biomedical research and commercialization, with a dedication to improving patient care: J Alex Ratti, MS - Founder & CEO (entrepreneurship, biomedical engineering) Matthew Hartman, PhD - inventor & scientific adviser (medicinal chemistry) Andrew Poklepovic, MD - scientific adviser (oncology, clinical trials) Joff Masukawa - business adviser (pharma commercialization) Join us at Light Switch Bio to make drugs less toxic, physically and financially!

Industry

Biotechnology Research

Company size

2-10 employees

Headquarters

Richmond, Virginia

Type

Privately Held

Founded

2018

Specialties

Photomedicine, Phototherapy, Photocage chemistry, Medicinal chemistry, Cancer therapeutics, Skin therapeutics, and Biomedical engineering